A synthetic triterpenoid that activates Nrf2 and suppresses NF-κB, bardoxolone methyl (CDDO-Me) significantly improved estimated GFR in early-phase CKD trials, including the BEAM and TSUBAKI studies—though the pivotal BEACON Phase III trial was halted due to increased cardiovascular events [109,110,111]. Here, NFKB1 is linked to chronic kidney disease.